Brokerages expect Heska Co. (NASDAQ: HSKA – Get Rating) to post $ 72.21 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Heska’s earnings, with estimates ranging from $ 70.90 million to $ 72.90 million. Heska posted sales of $ 64.93 million in the same quarter last year, which suggests a positive year-over-year growth rate of 11.2%. The firm is expected to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Heska will report full-year sales of $ 287.52 million for the current year, with estimates ranging from $ 285.30 million to $ 289.04 million. For the next fiscal year, analysts forecast that the firm will report sales of $ 318.64 million, with estimates ranging from $ 311.90 million to $ 331.95 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Heska.
Heska (NASDAQ: HSKA – Get Rating) last released its quarterly earnings data on Monday, May 9th. The medical research company reported $ 0.27 EPS for the quarter, beating the consensus estimate of $ 0.11 by $ 0.16. The business had revenue of $ 64.80 million for the quarter, compared to the consensus estimate of $ 66.32 million. Heska had a negative net margin of 5.04% and a negative return on equity of 0.95%. The company’s revenue was up 7.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $ 0.20 earnings per share.
Several equities research analysts have commented on HSKA shares. Piper Sandler dropped their price objective on shares of Heska from $ 210.00 to $ 190.00 and set an “overweight” rating on the stock in a report on Thursday, March 17th. StockNews.com initiated coverage on Heska in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Morgan Stanley decreased their price target on Heska from $ 190.00 to $ 161.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 1st. Alliance Global Partners reduced their price target on Heska from $ 240.00 to $ 150.00 in a research report on Tuesday, May 10th. Finally, JPMorgan Chase & Co. decreased their price target on Heska from $ 300.00 to $ 250.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $ 220.67.
NASDAQ HSKA opened at $ 88.19 on Friday. Heska has a 52 week low of $ 82.92 and a 52 week high of $ 275.94. The company has a quick ratio of 6.15, a current ratio of 6.73 and a debt-to-equity ratio of 0.23. The firm’s 50-day simple moving average is $ 130.34 and its two-hundred day simple moving average is $ 150.15.
Several hedge funds have recently bought and sold shares of HSKA. Northwestern Mutual Wealth Management Co. increased its position in shares of Heska by 132.0% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 232 shares of the company’s medical research stock worth $ 32,000 after purchasing an additional 132 shares during the last quarter. First Horizon Advisors Inc. increased its position in shares of Heska by 1,944.4% in the fourth quarter. First Horizon Advisors Inc. now owns 184 shares of the company’s medical research stock worth $ 33,000 after purchasing an additional 175 shares during the last quarter. Altshuler Shaham Ltd bought a new position in shares of Heska in the third quarter worth approximately $ 49,000. Pinebridge Investments LP bought a new position in shares of Heska in the fourth quarter worth approximately $ 55,000. Finally, Navigation Wealth Management Inc. bought a new position in shares of Heska in the fourth quarter worth approximately $ 68,000. Institutional investors own 95.94% of the company’s stock.
About Heska (Get Rating)
Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element and immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers.
Get a free copy of the Zacks research report on Heska (HSKA)
For more information about research offers from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heska Daily – Enter your email address below to receive a concise daily summary of the latest news and analyzes’ ratings for Heska and related companies with MarketBeat.com’s FREE daily email newsletter.